Serological Correlates of Protection against a GII.4 Norovirus.
about
The Vast and Varied Global Burden of Norovirus: Prospects for Prevention and ControlHuman Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades.B-Cell Responses to Intramuscular Administration of a Bivalent Virus-Like Particle Human Norovirus Vaccine.Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.Genetic and Epidemiologic Trends of Norovirus Outbreaks in the United States from 2013 to 2016 Demonstrated Emergence of Novel GII.4 Recombinant VirusesCorrelates of Protection against Norovirus Infection and Disease-Where Are We Now, Where Do We Go?Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding.Static and Evolving Norovirus Genotypes: Implications for Epidemiology and Immunity.A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulationNorovirus vaccines: Correlates of protection, challenges and limitationsIdentification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses.Impact of Pre-exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination.Recent advances in understanding norovirus pathogenesis.Seroprevalence in Household Raised Pigs Indicate High Exposure to GII Noroviruses in Rural Nicaragua.Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial.Norovirus-Specific Memory T Cell Responses in Adult Human Donors.Effects of disinfectants against norovirus virus-like particles predict norovirus inactivation.Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial.Characterization of virus-like particles derived from a GII.3 norovirus strain distantly related with current dominating strains.Seroprevalence of antibodies against GII.4 norovirus among children in Pune, India.Highlights of the 8th International Conference on Vaccines for Enteric Diseases: the Scottish Encounter To Defeat Diarrheal DiseasesSafety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial.Sequential Gastroenteritis Outbreaks in a Single Year Caused by Norovirus Genotypes GII.2 and GII.6 in an Institutional Setting
P2860
Q26749653-027008BE-5DF9-4D09-B0F8-8B07BADC946AQ30401642-1923BC42-ACB4-47BC-86B9-4F9D6D3827B1Q33654573-B80EF1D4-29A4-492F-9C28-EA8F94762AA1Q33703664-F91BFBAA-4570-4B4F-A4E9-508BD42D25E5Q33832855-E9284F7E-81EC-4374-AB44-6777403681E1Q35999334-E4B7CD30-3FDA-4BD5-9414-23EC2FE12E60Q36063949-53F768E7-4713-4000-9BC1-8BF9D5068721Q36254157-11151373-D79D-4DC4-A57D-5FB8074EDC4BQ36519453-71B40122-F5E5-403E-9672-928BC8487449Q36642590-4C3FD4FA-4374-4B73-AFA8-259FC17FBA70Q37135476-1CB45688-BC78-497E-9A06-E5C965D8631BQ37590280-E88D69C0-BD34-4138-8A5A-3C0852C52FE9Q38374766-167EA9A2-8D66-4712-8121-1575B60B59F8Q38816488-1D4B4CDC-8518-4BE1-B0FD-68C8C43AF129Q39770349-EFEF97EA-E4D2-46D2-96D5-2B2F5C7F9062Q40080595-E0ED28E8-4F62-49C5-8129-C659CD4B9682Q40502202-BA63C244-7ECF-4287-AB3B-AF5E04D21715Q40565387-83376FBC-3966-47D8-A3E6-CF3FC512808DQ40632645-4A9A8BA3-C70D-47CF-A35E-8DA31A622986Q40731773-338092CF-1121-4350-9DEB-852D3CAFD7B7Q40794900-A8D9C3BE-2E26-4949-B093-03162F24C64BQ42554197-5CAE5A4D-A910-4085-A7C1-6995968F5106Q47579651-77537C7C-099C-4BBB-8329-20C5408140DAQ57826949-59EC315D-BC73-482A-ADC6-5AEA7C792777
P2860
Serological Correlates of Protection against a GII.4 Norovirus.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Serological Correlates of Protection against a GII.4 Norovirus.
@ast
Serological Correlates of Protection against a GII.4 Norovirus.
@en
type
label
Serological Correlates of Protection against a GII.4 Norovirus.
@ast
Serological Correlates of Protection against a GII.4 Norovirus.
@en
prefLabel
Serological Correlates of Protection against a GII.4 Norovirus.
@ast
Serological Correlates of Protection against a GII.4 Norovirus.
@en
P2093
P2860
P50
P356
P1476
Serological Correlates of Protection against a GII.4 Norovirus.
@en
P2093
Anthony Edmonds
Antone R Opekun
Astrid Borkowski
Christine L Moe
David I Bernstein
Frank Baehner
G Marshall Lyon
Jennifer Ferreira
Jill Barrett
John J Treanor
P2860
P304
P356
10.1128/CVI.00196-15
P577
2015-06-03T00:00:00Z